Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 33 articles:
HTML format
Text format



Single Articles


    April 2017
  1. BRIZZOLARA A, Benelli R, Vene R, Barboro P, et al
    The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Cancer Lett. 2017 Apr 25. pii: S0304-3835(17)30285.
    PubMed     Text format     Abstract available


    March 2017
  2. LIN SJ, Chou FJ, Li L, Lin CY, et al
    Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Cancer Lett. 2017 Mar 31. pii: S0304-3835(17)30217.
    PubMed     Text format     Abstract available


  3. TAKAYAMA K, Inoue T, Narita S, Maita S, et al
    Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Cancer Lett. 2017 Mar 31. pii: S0304-3835(17)30216.
    PubMed     Text format     Abstract available


  4. O'MALLEY J, Kumar R, Kuzmin A, Pliss A, et al
    Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer.
    Cancer Lett. 2017 Mar 23. pii: S0304-3835(17)30199.
    PubMed     Text format     Abstract available


  5. GUO C, Yeh S, Niu Y, Li G, et al
    Targeting Androgen Receptor versus Targeting Androgens to suppress Castration Resistant Prostate Cancer.
    Cancer Lett. 2017 Mar 18. pii: S0304-3835(17)30195.
    PubMed     Text format     Abstract available


  6. KANG TS, Wang W, Zhong HJ, Dong ZZ, et al
    An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-kappaB.
    Cancer Lett. 2017 Mar 16. pii: S0304-3835(17)30180.
    PubMed     Text format     Abstract available


  7. EL BEZAWY R, Cominetti D, Fenderico N, Zuco V, et al
    miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis.
    Cancer Lett. 2017 Mar 5. pii: S0304-3835(17)30150.
    PubMed     Text format     Abstract available


    February 2017
  8. MARTINEZ DE PINILLOS BAYONA A, Woodhams JH, Pye H, Hamoudi RA, et al
    Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: an in vitro study in 2D and 3D prostate cancer models.
    Cancer Lett. 2017 Feb 18. pii: S0304-3835(17)30127.
    PubMed     Text format     Abstract available


    January 2017
  9. LIN LC, Gao AC, Lai CH, Hsieh JT, et al
    Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.
    Cancer Lett. 2017 Jan 18. pii: S0304-3835(17)30041.
    PubMed     Text format     Abstract available


  10. ZHANG L, Peng S, Dai X, Gan W, et al
    Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30021.
    PubMed     Text format     Abstract available


    December 2016
  11. TONG D, Liu Q, Liu G, Xu J, et al
    Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis.
    Cancer Lett. 2016 Dec 30. pii: S0304-3835(16)30801.
    PubMed     Text format     Abstract available


    November 2016
  12. WU H, Zhang L, Gao X, Zhang X, et al
    Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Cancer Lett. 2016 Nov 1. pii: S0304-3835(16)30667.
    PubMed     Text format     Abstract available


    October 2016
  13. RAMALHO-CARVALHO J, Martins JB, Cekaite L, Sveen A, et al
    Epigenetic Disruption of miR-130a Promotes Prostate Cancer By Targeting SEC23B and DEPDC1.
    Cancer Lett. 2016 Oct 27. pii: S0304-3835(16)30649.
    PubMed     Text format     Abstract available


  14. WU F, Dai X, Gan W, Wan L, et al
    Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
    Cancer Lett. 2016 Oct 22. pii: S0304-3835(16)30641.
    PubMed     Text format     Abstract available


  15. TSAI YC, Chen WY, Siu MK, Tsai HY, et al
    Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6.
    Cancer Lett. 2016 Oct 13. pii: S0304-3835(16)30626.
    PubMed     Text format     Abstract available


  16. JING P, Cao S, Xiao S, Zhang X, et al
    Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
    Cancer Lett. 2016 Oct 6. pii: S0304-3835(16)30610.
    PubMed     Text format     Abstract available


    September 2016
  17. HORMAECHEA-AGULLA D, Gomez-Gomez E, Ibanez-Costa A, Carrasco-Valiente J, et al
    Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30564.
    PubMed     Text format     Abstract available


  18. INGERSOLL MA, Miller DR, Martinez O, Wakefield CB, et al
    Statin Derivatives as Therapeutic Agents for Castration-Resistant Prostate Cancer.
    Cancer Lett. 2016 Sep 26. pii: S0304-3835(16)30550.
    PubMed     Text format     Abstract available


    June 2016
  19. CALGANI A, Delle Monache S, Cesare P, Vicentini C, et al
    Leptin contributes to long-term stabilization of HIF-1alpha in cancer cells subjected to oxygen limiting conditions.
    Cancer Lett. 2016;376:1-9.
    PubMed     Text format     Abstract available


  20. QIN F, Song Z, Chang M, Song Y, et al
    Recurrent cis-SAGe chimeric RNA, D2HGDH-GAL3ST2, in prostate cancer.
    Cancer Lett. 2016 Jun 17. pii: S0304-3835(16)30373.
    PubMed     Text format     Abstract available


    May 2016
  21. WANG R, Lin W, Lin C, Li L, et al
    ASC-J9 suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Cancer Lett. 2016 May 24. pii: S0304-3835(16)30331.
    PubMed     Text format     Abstract available


  22. LIU N, Mei L, Fan X, Tang C, et al
    Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway.
    Cancer Lett. 2016 May 11. pii: S0304-3835(16)30305.
    PubMed     Text format     Abstract available


    April 2016
  23. DAS TP, Suman S, Papu John AM, Pal D, et al
    Activation of AKT negatively regulates the pro-apoptotic function of death-associated protein kinase 3 (DAPK3) in prostate cancer.
    Cancer Lett. 2016 Apr 25. pii: S0304-3835(16)30263.
    PubMed     Text format     Abstract available


  24. CHOI H, Lee SH, Um SJ, Kim EJ, et al
    CACUL1 functions as a negative regulator of androgen receptor in prostate cancer cells.
    Cancer Lett. 2016 Apr 13. pii: S0304-3835(16)30254.
    PubMed     Text format     Abstract available


  25. WEN S, Tian J, Niu Y, Li L, et al
    ASC-J9, and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Cancer Lett. 2016 Apr 1. pii: S0304-3835(16)30203.
    PubMed     Text format     Abstract available


    March 2016
  26. BARAKAT DJ, Mendonca J, Barberi T, Zhang J, et al
    C/EBPbeta regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion.
    Cancer Lett. 2016 Mar 8. pii: S0304-3835(16)30141.
    PubMed     Text format     Abstract available


  27. ZHANG A, Zhang J, Kaipainen A, Lucas JM, et al
    Long non-coding RNA, a newly deciphered "code" in prostate cancer.
    Cancer Lett. 2016 Mar 7. pii: S0304-3835(16)30139.
    PubMed     Text format     Abstract available


  28. HWANG JE, Joung JY, Shin SP, Choi MK, et al
    Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
    Cancer Lett. 2016;372:57-64.
    PubMed     Text format     Abstract available


    February 2016
  29. SINGH S, Zheng Y, Jagadeeswaran G, Ebron JS, et al
    Deep sequencing of small RNA libraries from human prostate epithelial and stromal cells reveal distinct pattern of microRNAs primarily predicted to target growth factors.
    Cancer Lett. 2016;371:262-73.
    PubMed     Text format     Abstract available


  30. CHEN JX, Li G, Wang H, Liu A, et al
    Dietary tocopherols inhibit PhIP-induced prostate carcinogenesis in CYP1A-humanized mice.
    Cancer Lett. 2016;371:71-8.
    PubMed     Text format     Abstract available


    January 2016
  31. SHIAO SL, Chu GC, Chung LW
    Regulation of prostate cancer progression by the tumor microenvironment.
    Cancer Lett. 2016 Jan 28. pii: S0304-3835(15)00773.
    PubMed     Text format     Abstract available


  32. FANG Z, Xu C, Li Y, Cai X, et al
    A feed forward regulatory loop between androgen receptor and PlncRNA-1 promotes prostate cancer progression.
    Cancer Lett. 2016 Jan 22. pii: S0304-3835(16)30003.
    PubMed     Text format     Abstract available


    December 2015
  33. KOUSHYAR S, Jiang WG, Dart DA
    Unveiling the potential of prohibitin in cancer.
    Cancer Lett. 2015;369:316-22.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: